



RESEARCH UPDATE

BUTLER CENTER FOR RESEARCH JANUARY 2014

Prescription Opioids and Dependence

The misuse of prescription opioids (PO) has reached a national epidemic affecting millions of people. The purpose of this Research Update is to provide information on the prevalence, associated risk factors, and potential treatments for PO use and dependence.

Prevalence of Use and Dependence

According to recent estimates approximately 5% of the U.S. population reported misusing a PO during the past year, a rate higher than any other illicit substance with the exception of marijuana. Rates of PO dependence and PO-related emergency room (ER) visits increased dramatically during the past decade. Between 2004 and 2012 the number of PO-related admissions to substance abuse programs increased by 65% (from 1.4 million to 2.1 million), while the number of ER visits due to PO overdose increased by over 200%, exceeding ER visits due to cocaine, alcohol, or heroin overdose.^{1,2} The increase in PO-related deaths and substance abuse treatment admissions between 1999 and 2010 coincides with a dramatic increase in pharmaceutical sales of POs (see Figure 1).³

Vulnerability Factors

Findings from epidemiological and clinical research suggest that risk for PO misuse and dependence differs depending on one's age, gender, and chronic pain status. National rates of opioid dependence increased significantly among adolescents and young adults over the past decade and the estimated number of opioid-related ER visits has more than doubled among individuals younger than 21 years of age (from 13,735 in 2004 to 29,196 in 2008).⁴ There are also gender differences in PO misuse such that men have significantly higher lifetime rates of nonmedical use of POs compared to women (15.9% vs. 11.2%).⁵ The estimated incidence of PO misuse among those with chronic pain is approximately 20%, far exceeding the 5% incidence rate in the general population.⁶


Prevention

In April 2011, the White House initiated a multiagency response to the opioid crisis. The plan involves: 1) promoting youth, parent, and physician education; 2) encouraging research on trends of PO misuse and effective treatments; 3) developing more efficient methods to monitor prescriptions of opioids; and 4) increasing law enforcement resources that target opioid prescription malpractice.⁷

Efforts are also being made to establish safeguards against over prescription of opioids at the clinical level. Additional training and the use of screening tools designed to help physicians identify patients at risk for

> CONTINUED AT RIGHT

Figure 1: Increase in the rates of opioid pain relievers (OPR) overdose deaths, treatment admissions, and kilograms of opioid pain relievers sold in the United States between 1999 and 2010.



Source: National Vital Statistics System, 1999–2008; Automation of Reports and Consolidated Orders System (ARCOS) of the Drug Enforcement Administration (DEA), 1999–2010; Treatment Episode Data Set, 1999–2009

THE HAZELDEN EXPERIENCE

Comprehensive Opioid Response with Twelve Steps (COR-12)

Comprehensive Opioid Response with Twelve Steps (COR-12) is Hazelden's response to the nation's epidemic of opioid addiction. Hazelden's COR-12 team consists of medical, clinical, and research professionals who's collective goal is to improve the lives of those suffering from opioid addiction. We are applying our mission, vision, values, and the latest scientific evidence to address the specific needs of opioid dependent individuals. This innovative program encompasses the whole spectrum of recovery—from prerecovery, to recovery initiation, to ongoing and lifelong recovery support services. The COR-12 treatment path includes group therapy and lectures that focus on opioid addiction as well as extended, adjunctive medication assisted treatment (MAT) as a means to help people achieve a stable, Twelve Step–based recovery lifestyle and ultimate abstinence from opioids. Components of the MAT plan include the possible use of two medications—buprenorphine/naloxone (Suboxone[®]) and extended release naltrexone (Vivitrol[®])—which are offered under closely supervised care. These medications have been shown to improve the likelihood of abstinence from opioids, boost retention and engagement in treatment, reduce cravings for opioids, and lower relapse rates.^{14,17} For additional information please visit hazelden.org/cor12.

Professionals in Residence Program

Hazelden's Professionals in Residence Program teaches doctors and other health care professionals to recognize and assess substance abuse and dependence, including abuse of prescribed pain medications. For additional information please visit hazelden.org/pir.

> CONTINUED FROM LEFT

developing opioid dependence are becoming common and an emphasis is being placed on alternatives to POs for patients who are at increased risk.⁸

Efforts at the community level primarily focus on addressing PO misuse among youth. Community- and school-based prevention programs that enhance life skills and academic performance, improve family relationships, and reduce risky behaviors

> CONTINUED ON BACK

Prescription Opioids and Dependence

such as substance misuse and conduct problems have shown promise in preventing the misuse of POs. Spoth et al. (2013) examined the long-term effects of three such programs on PO misuse among sixth- and seventh-graders from over 70 schools. The results of the study indicated that membership in the youth prevention programs was associated with significant reductions in PO misuse 6–14 years following program completion.⁹

Treatment

Cognitive Behavioral Treatment

Research suggests cognitive-behavioral counseling and close monitoring may deter misuse of POs among those suffering from chronic pain. In a study by Jamison et al. (2010), chronic pain patients were randomly assigned to a standard therapy control condition or an experimental condition where they received monthly urine screens, treatment compliance checks, and motivational counseling. After 6 months patients in the experimental (versus control) group were significantly less likely to self-report PO misuse and have abnormal urine toxicology results.¹⁰

Pharmacological Treatments


Pharmacotherapies also show promise in the treatment of PO dependence. Findings from clinical research indicate that the partial opioid agonist buprenorphine (Suboxone®, Subutex®) decreases craving and relapse and improves treatment retention across a range of demographics and treatment contexts.^{11, 12, 13, 14} The extended-release injectable form of naltrexone (Vivitrol®) blocks the pharmacological and psychologically reinforcing effects of opioids and has also shown promise in treating opioid dependence.^{15, 16}

In a rigorous study by Sigmon et al. (2013), the efficacy of buprenorphine and naltrexone in treating PO dependence was examined in a randomized double-blind 12-week clinical trial. Seventy PO patients in an outpatient clinic were randomly assigned to 1, 2, or 4 weeks of a buprenorphine tapering regimen that was followed by naltrexone therapy. All patients received standard behavioral therapy throughout the 12-week period. At 12 weeks, patients in the 4-week taper condition were significantly more likely to remain abstinent from opioids and were less likely to drop out of treatment compared to the other groups.¹⁷

Summary and Conclusion

While the increasing number of people dependent on POs is disturbing, steps are being made to address the problem. Concerted efforts from clinicians, researchers, policy makers, and community leaders are enhancing clinical awareness, improving diagnostic accuracy, and facilitating the alignment of clinical and community resources to effectively prevent and treat PO dependence. It is important to note that pain medications are used appropriately by millions of Americans with legitimate needs; however, the consequences of PO misuse warrant extra care in their prescription and use.

Figure 2: Deaths from Opioid Pain Relievers Exceed Those of All Illegal Drugs



Source: CDC, Morbidity and Mortality Report, 60 [43]: 1489, 2011

hazelden.org

BUTLER CENTER FOR RESEARCH JANUARY 2014

The Butler Center for Research informs and improves recovery services and produces research that benefits the field of addiction treatment. We are dedicated to conducting clinical research, collaborating with external researchers, and communicating scientific findings.

Justin Anker, Ph.D., Research Scientist

If you have questions, or would like to request copies of Research Update, please call 800-257-7800, ext. 4405, email butlerresearch@hazelden.org, or write BC 4, P.O. Box 11, Center City, MN 55012-0011.



References

1. Substance Abuse and Mental Health Services Administration, *Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings*. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
2. Substance Abuse and Mental Health Services Administration, *Drug abuse warning network (DAWN), 2011: National estimates of drug-related emergency department visits*. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
3. Kenan, K., Mack, K., & Paulozzi, L. (2012). Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. *Open Medicine*, 6(2), e41.
4. Johnston, L. (2010). *Monitoring the future: National results on adolescent drug use: Overview of key findings (No. 9)*. DIANE Publishing.
5. Back, S. E., Payne, R. L., Simpson, A. N., & Brady, K. T. (2010). Gender and prescription opioids: Findings from the National Survey on Drug Use and Health. *Addictive Behaviors*, 35(11), 1001–1007.
6. Sehgal, N., Manchikanti, L., & Smith, H. S. (2012). PO abuse in chronic pain: A review of opioid abuse predictors and strategies to curb opioid abuse. *Pain Physician*, 15(3).
7. Office of National Drug Control Policy. *Epidemic: Responding to America's prescription drug abuse crisis*. April 19, 2011. www.whitehousedrugpolicy.gov/news/press11/041911.html.
8. Cicero, T. J., Lynskey, M., Todorov, A., Inciardi, J. A., & Surratt, H. L. (2008). Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. *Pain*, 139(1), 127–135.
9. Spoth, R., Trudeau, L., Shin, C., Ralston, E., Redmond, C., Greenberg, M., & Feinberg, M. (2013). Longitudinal effects of universal preventive intervention on prescription drug misuse: Three randomized controlled trials with late adolescents and young adults. *American Journal of Public Health*, 103(4), 665–672.
10. Jamison, R. N., Ross, E. L., Michna, E., Chen, L. Q., Holcomb, C., & Wasan, A. D. (2010). Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. *Pain*, 150(3), 390–400.
11. Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011). Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. *Archives of Internal Medicine*, 171(5), 425.
12. Magura, S., Lee, S. J., Salsitz, E. A., Kolodny, A., Whitley, S. D., Taubes, T., ... & Rosenblum, A. (2007). Outcomes of buprenorphine maintenance in office-based practice. *Journal of Addictive Diseases*, 26(2), 13–23.
13. Soeffing, J. M., Martin, L. D., Fingerhood, M. I., Jasinski, D. R., & Rastegar, D. A. (2009). Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year. *Journal of Substance Abuse Treatment*, 37(4), 426–430.
14. Subramaniam, G. A., Warden, D., Minhajuddin, A., Fishman, M. J., Stitzer, M. L., Adinoff, B., ... & Woody, G. E. (2011). Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. *Journal of the American Academy of Child & Adolescent Psychiatry*, 50(11), 1120–1128.
15. Fishman, M. J., Winstanley, E. L., Curran, E., Garrett, S., & Subramaniam, G. (2010). Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case series and feasibility. *Addiction*, 105(9), 1669–1676.
16. Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *The Lancet*, 377(9776), 1506–1513.
17. Sigmon, S. C., Dunn, K. E., Saulsgiver, K., Patrick, M. E., Badger, G. J., Heil, S. H., ... & Higgins, S. T. (2013). A randomized, double-blind evaluation of buprenorphine taper duration in primary opioid abusers. *JAMA Psychiatry*, 70(12), 1347–1354.